Company / Financials
Neurocrine Biosciences Financials
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$2.9B
FY2025 · +21.4% YoY
Net Income
$478.6M
FY2025 · +40.2% YoY
Profit Margin
16.7%
FY2025 · net income / revenue
ROE
14.7%
FY2025 · return on equity
Total Assets
$4.6B
FY2025
Total Debt
-
FY2025
Equity
$3.3B
FY2025
ROA
10.3%
FY2025 · return on assets
Statement paths
Financial highlights
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$2.9B+21.4% YoYNet Income HistoryProfit after all expenses and taxes$478.6M+40.2% YoYCost of Revenue HistoryDirect costs of producing goods and services sold$52.1M+53.2% YoYOperating Income HistoryProfit from core business operations before interest and taxes$619.1M+8.5% YoYSG&A Expense HistorySelling, general, and administrative expenses$1.2B+14.8% YoYR&D Expense HistoryResearch and development spending$1.0B+38.9% YoYInterest Expense HistoryCost of borrowing and debt obligations$4.6MIncome Tax HistoryTotal income tax expense$226.8M+56.7% YoYEPS (Basic) HistoryBasic earnings per share$2.56+59.0% YoYEPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles$2.47+58.3% YoY